Royalty Pharma EVP gets 26,626 share award

Royalty Pharma plc EVP & Vice Chairman Christopher Hite reported an indirect acquisition of 26,626 Class A Ordinary Shares on February 11, 2026.

Rhea-AI Filing Summary

Royalty Pharma plc EVP & Vice Chairman Christopher Hite reported an indirect acquisition of 26,626 Class A Ordinary Shares on February 11, 2026. The shares were granted at $0 per share in an exempt equity award settlement under Rule 16b-3.

After this transaction, 685,136 Class A Ordinary Shares are held indirectly through SCH Investment Partners LLC, and 70,000 Class A Ordinary Shares are held directly. In addition, family vehicles hold interests exchangeable into 866,410 Class A shares and Class E shares exchangeable into 1,238,789 Class A shares, with the Class E shares subject to vesting conditions.

Insider Trade Summary

Grant/Award: 26,626 shares

Grant/Award 2 txns

Insider Hite Christopher

Role EVP & Vice Chairman

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	26,626	$0.00	$0.00
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 685,136 shares (Indirect, By SCH Investment Partners LLC); Class A Ordinary Shares — 70,000 shares (Direct)

Footnotes (1)

1. F1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Royalty Pharma (RPRX) report for Christopher Hite?

Christopher Hite reported an indirect acquisition of 26,626 Class A Ordinary Shares of Royalty Pharma on February 11, 2026. The shares were granted at $0 per share in connection with the settlement of Equity Performance Awards under Rule 16b-3.

How many Royalty Pharma (RPRX) shares does Christopher Hite own after this filing?

Following the reported transaction, 685,136 Class A Ordinary Shares are held indirectly through SCH Investment Partners LLC, and 70,000 Class A Ordinary Shares are held directly. These amounts reflect Hite’s reported beneficial ownership after the February 11, 2026 equity award settlement.

Was the Royalty Pharma (RPRX) insider acquisition an open-market purchase?

No, the 26,626 Class A Ordinary Shares were acquired at $0 per share as an exempt grant under Rule 16b-3. They arose from the settlement of Equity Performance Awards, rather than from an open-market buy or discretionary cash purchase.

How are Christopher Hite’s Royalty Pharma (RPRX) shares held?

After the transaction, Hite reports indirect ownership of 685,136 Class A shares through SCH Investment Partners LLC and direct ownership of 70,000 Class A shares. The filing classifies these holdings separately as indirect and direct beneficial ownership positions.

What additional exchangeable interests tied to Royalty Pharma (RPRX) does Christopher Hite report?

Family vehicles associated with Hite hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A shares. They also hold Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,238,789 Class A shares, subject to vesting conditions.

What does Rule 16b-3 treatment mean for this Royalty Pharma (RPRX) award?

The filing notes the acquisition is exempt under Rule 16b-3, meaning it arises from a board-approved compensation arrangement. The 26,626 Class A shares were issued through settlement of Equity Performance Awards, not through trading on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hite Christopher

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Vice Chairman

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	02/11/2026		A		26,626(1)	A	$0	685,136	I	By SCH Investment Partners LLC
Class A Ordinary Shares								70,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,238,789 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.